PARKIN Inactivation Links Parkinson's Disease to Melanoma

Journal of the National Cancer Institute

Volumn 108, Issue 3, 2016, Pages

  Hu, Hui Han ^a,b,c   Kannengiesser, Caroline ^b,c   Lesage, Suzanne ^d   André, Jocelyne ^a,c   Mourah, Samia ^a   Michel, Laurence ^a,c   Descamps, Vincent ^a,b   Basset Seguin, Nicole ^a,c   Bagot, Martine ^a,c   Bensussan, Armand ^a,d   Lebbé, Céleste ^a   Deschamps, Lydia ^b,c   Saiag, Philippe ^e   Leccia, Marie Thérèse ^f   Bressac De Paillerets, Brigitte ^g   Tsalamlal, Amel ^b,c   Kumar, Rajiv ^h   Klebe, Stephan ⁱ   Grandchamp, Bernard ^b,c   Andrieu Abadie, Nathalie ^j   Thomas, Luc ^k   Brice, Alexis ^l   Dumaz, Nicolas ^a,c   Soufir, Nadem ^a,b,c   more..

^a SAINT LOUIS HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j CANCER RESEARCH CENTER OF TOULOUSE   (France)

^k HÔTEL DIEU   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PARKIN; DNA; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ASSOCIATION; FEMALE; FRAMESHIFT MUTATION; GENE DOSAGE; GENE INACTIVATION; GENETIC TRANSFECTION; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL LINE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PARKINSON DISEASE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLICING DEFECT; WESTERN BLOTTING; CASE CONTROL STUDY; DNA SEQUENCE; FRANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; MIDDLE AGED; ODDS RATIO; PROTEIN SPLICING; RISK; SKIN NEOPLASMS; TUMOR CELL LINE;

ADULT; AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; FRAMESHIFT MUTATION; FRANCE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GERM-LINE MUTATION; HUMANS; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; MUTATION, MISSENSE; ODDS RATIO; PARKINSON DISEASE; PROTEIN SPLICING; RISK; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84962532680     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv340     Document Type: Article

References (22)

1. Bertoni JM, Arlette JP, Fernandez HH, et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol. 2010;67(3):347-52.
2. Garber K. Parkinson's disease and cancer: the unexplored connection. J Natl Cancer Inst. 2010;102(6):371-374.
3. Liu R, Gao X, Lu Y, et al. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011;76(23):2002-2009.
4. Rugbjerg K, Friis S, Lassen CF, et al. Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. International journal of cancer. J Int Cancer. 2012;131(8):1904-1911.
5. Baade PD, Fritschi L, Freedman DM. Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients. Neuroepidemiology. 2007;28(1):16-20.
6. Devine MJ, Plun-Favreau H, Wood NW. Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer. 2011;11(11):812-823.
7. Inzelberg R, Rabey JM, Melamed E, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. J Neural Transm. 2011;118(8):1199-1207.
8. Pan T, Li X, Jankovic J. The association between Parkinson's disease and melanoma. International journal of cancer. J Int Cancer. 2011;128(10):2251-2260.
9. Kay DM, Stevens CF, Hamza TH, et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology. 2010;75(13):1189-1194.
10. Exner N, Treske B, Paquet D, et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neuroscience. 2007;27(45):12413-12418.
11. Narendra D, Tanaka A, Suen DF, et al. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183(5):795-803.
12. Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol. 1998;44(6):935-941.
13. Toma MI, Grosser M, Herr A, et al. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia. 2008;10(7):634-642.
14. Veeriah S, Taylor BS, Meng S, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010;42(1):77-82.
15. Poulogiannis G, McIntyre RE, Dimitriadi M, et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A. 2010;107(34):15145-15150.
16. Sun X, Liu M, Hao J, et al. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle. 2013;12(7):1133-1141.
17. Gong Y, Zack TI, Morris LG, et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet. 2014;46(6):588-594.
18. Marquette A, Andre J, Bagot M, et al. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol. 2011;18(5):584-591.
19. Nuytemans K, Theuns J, Cruts M, et al. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mut. 2010;31(7):763-780.
20. Gast A, Scherer D, Chen B, et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer. 2010;49(8):733-745.
21. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012;12(5):349-361.
22. Yeo CW, Ng FS, Chai C, et al. Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res. 2012;72(10):2543-2553.